| Literature DB >> 34236802 |
Murat Günday1, Zülfükar Kadir Saritaş2, Hasan Hüseyin Demirel3, Aziz Bülbül4, Tuba Berra Saritaş5, Fatma Görücü2, Necip Becit1.
Abstract
INTRODUCTION: In this study, Anzer propolis, which can only be obtained from the Eastern Black Sea region in Turkey, is studied for its effect on spinal cord ischemia/reperfusion injury.Entities:
Keywords: Animals; Biomarkers; Ischemia; Peroxidase; Propolis; Rabbits; Reperfusion; Solubility
Mesh:
Substances:
Year: 2022 PMID: 34236802 PMCID: PMC8973139 DOI: 10.21470/1678-9741-2020-0430
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Electron microscopic scoring criteria for specimens.
| I/R group | Pr group |
| ||
|---|---|---|---|---|
| Intracellular edema | 4.25±0.96 | 2.00±0.00 | 0.011 | |
| None | 0 | |||
| + | 1 | |||
| ++ | 2 | |||
|
| ||||
| Normal myelin layers | 0 | |||
| Splitting of myelin layers | 1 | |||
| Fragmentations of myelin layers | 2 | |||
| Honeycomb appearance | 3 | |||
|
| ||||
| None | 0 | |||
| Yes | 1 | |||
|
| ||||
| Normal | 0 | |||
| Mild | 1 | |||
| Severe | 2 |
I/R=ischemia/reperfusion; Pr=propolis
Spectrometry analysis of propolis.
| Compounds | % ratio |
|---|---|
| 2-methoxy-4-vinylphenol | 3.30 |
| 6-phenyl-5-hexenoic acid, methyl | 1.02 |
| Guaiol | 0.40 |
| Dodecanoic acid ethyl ester | 1.11 |
| Agarospirol | 0.95 |
| Bicyclo[4.4.0]dec-1-ene, 2-isopr | 0.88 |
| 2-naphthalenemethanol, decahydro | 4.60 |
| 2-naphthalenemethanol, 1,2,3,4,4 | 4.31 |
| Naphthalene, 1,2,4a,5,6,8a-hexah | 0.74 |
| (1R,7S,E)-7-isopropyl-4,10-dimet. | 0.39 |
| Alpha-bisabolol | 3.79 |
| Benzyl benzoate | 1.83 |
| 7-(2-hydroxypropan-2-yl)-1,4a-di | 1.01 |
| (-)-spathulenol | 0.38 |
| (1R,4aR,7R,8aR)-7-(2-Hydroxyprop | 4.72 |
| Tetradecanoic acid, ethyl ester | 0.63 |
| Hexadecanoic acid, ethyl ester | 4.26 |
| 4b,8-dimethyl-2-isopropylphenant | 0.10 |
| (E)-cinnamyl benzoate | 1.53 |
| Benzyl cinnamate | 2.98 |
| Heptadecanoic acid, ethyl ester | 0.56 |
| 1-propene-1,2,3-tricarboxylic ac | 0.28 |
| Linoleic acid ethyl ester | 2.41 |
| Ethyl oleate | 10.23 |
| 2-propenoic acid, 3-(4-hydroxy-3.. | 1.72 |
| Benzaldehyde, 4,6-dimethoxy-2,3-. | 0.77 |
| Octadecanoic acid, ethyl ester | 1.74 |
| Trans-ferulic acid | 1.54 |
| Butyl citrate | 2.44 |
| (1aR,4aS,8aS)-4a,8,8-trimethyl-1.. | 2.44 |
| 2-phenanthrenol, 4b,5,6,7,8,8a,9. | 1.72 |
| Ferruginol | 0.55 |
| 1-phenanthrenemethanol, 1,2,3,4,... | 0.64 |
| 4H-1-benzopyran-4-one,2,3-dihydro | 6.35 |
| Cinnamyl cinnamate | 3.58 |
| Eicosanoic acid, ethyl ester | 2.97 |
| Cedrol | 1.45 |
| 2-(acetoxymethyl)-3-(methoxycarb.. | 0.55 |
| Pyrido[2,3-d]pyrimidine, 4-phenyl- | 0.45 |
| Benzyl (E)-ferulate | 4.44 |
| 4H-1-benzopyran-4-one, 5-hydroxy.. | 9.07 |
| 2-bromo-4,5-dimethoxycinnamic acid | 0.53 |
| (1R,4aR,4bS,7R,10aR)-1,4a,7-Trim... | 3.02 |
Biochemical analysis results in groups (mean±SD).
| Parameter/Group | 0th hour | 24th hour | 48th hour |
|---|---|---|---|
|
| 4,8900±,23956c | 10,3350±,53293a | 7,4367±,52164b |
|
| 4,9683±,28891b | 9,3500±,50484a | 8,3883±,38178a |
|
| 0.763 | 0.303 | 0.298 |
|
| 43,5933±1,81007c | 149,6283±15,75694a | 81,0450±4,68628b |
|
| 39,0800±2,90564c | 111,2600±3,28355a | 59,6033±5,26723b |
|
| 0.168 | 0.066 | 0.022 |
|
| 21,4983±,84374 | 255,711111183±17,47462 | 145,1700±17,44557 |
|
| 24,4500±3,57613 | 246,3683±32,18286 | 85,2800±10,33481 |
|
| 0.425 | 0.759 | 0.040 |
|
| 4,2133±,38473b | 5,9467±,55778ab | 7,5783±,50105a |
|
| 4,5233±,24887b | 4,6183±,18816b | 5,7117±,27411a |
|
| 0.548 | 0.037 | 0.023 |
|
| 1,3820±,06135b | 1,6760±,07814a | 1,8500±,08438a |
|
| 1,4380±,05970b | 1,5340±,04632b | 1,7700±,04494a |
|
| 0.548 | 0.015 | 0.642 |
|
| 187,5667±6,12962c | 357,3117±24,00794a | 252,1100±15,60926b |
|
| 197,2983±8,85513b | 320,6283±38,75100a | 205,7600±14,84168b |
|
| 0.339 | 0.219 | 0.012 |
|
| 4,8483±,22494b | 6,0633±,26670a | 6,6767±,42214a |
|
| 5,0733±,25741 | 5,5700±,19471 | 4,8633±,18903 |
|
| 0.599 | 0.099 | 0.002 |
|
| 6,9383±,41051 | 7,1500±,54968 | 7,3517±,35899 |
|
| 7,3467±,51261 | 7,2533±,23937 | 7,7167±,21066 |
|
| 0.061 | 0.833 | 0.241 |
ICAM-1=internal adhesion molecule-1; IL-1=interleukin 1; IL-6=interleukin 6; IMA=ischemia-modified albumin; I/R=ischemia/reperfusion; MPO=myeloperoxidase; Pr=propolis; TAS=total antioxidant capacity; TNF-α=tumor necrosis factor-alpha; TOS=total oxidant capacity
Histopathological evaluation of propolis in spinal cord ischemia/reperfusion injury in rabbits.
| Histopathological finding | I/R | I/R+Propolis | F |
| |||
|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||||
| Spinal cord | Chromatolysis and Nissl granule loss | 2.43 | 1.03 | 0.90 | 0.80 | 1.553 | 0.016 |
| Spherule formations | 2.43 | 1.03 | 0.88 | 1.03 | 0.001 | 0.027 | |
| Focal MCI areas | 1.58 | 0.87 | 0.55 | 0.60 | 0.602 | 0.038 | |
| TUNEL | Apoptotic index data | 0.42 | 0.65 | 0.28 | 0.44 | 0.804 | 0.001 |
IR=ischemia/reperfusion; MCI=mononuclear cell infiltration; SD=standard deviation
Fig. 1Effects of propolis on the damage caused by ischemia/reperfusion of the spinal cords of rabbits. All shapes are stained with HE. (A2) 10x and 200 µm VE (A1) 20x and 100 µm were used as the original magnification. A1: Thick arrows: chromatolysis and loss of Nissl granules in neurons. Thin arrow: formations of diffuse spherical shape. Arrowhead: focal mononuclear cell infiltration areas. A2: Thick arrow: chromatolysis and loss of Nissl granules in multipolar neurons. Thin arrows: spherulite formations.
Note: cellsstained brown show TUNEL-positive cells (arrow). (A), (B) 10x and 200 µm were used as the original magnification.
Fig. 3Electron microscopy examination of the spinal cord. The image on the left side shows a view of a subject from the I/R group. a: axonal/myelin separation and axoplasmic dissolution. ms: myelin separation. The image on the right side shows regular myelin sequences in the electron microscope view of a subject in the group that received propolis.
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
|
|
|
| ||
| Authors' roles & responsibilities | |
|---|---|
| MG | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| ZKS | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| HHD | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| AB | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| TBS | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| FG | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| NB | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |